



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
Chris M. Farnet et al.

Examiner: Kathleen M. Kerr

Group Art Unit: 1652

Serial No.: 09/976,059

Attorney docket no. 3002-2US  
(formerly 3019-US)

Filed: Oct. 15, 2001

For: GENE CLUSTER FOR RAMOPLANIN BIOSYNTHESIS

FEE TRANSMITTAL SHEET

Commissioner for Patents  
Washington, D.C. 20231

Sir: The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.

The claim amendment fee has been estimated as follows:

	Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Rate (Small Entity)	Additional Fee
Total	21	24	0	X \$9	\$0
Independent	1	6	0	X \$43	\$0

First Presentation of Multiple Dependent Claim

\$145 \$0

**TOTAL: \$0**

Although the fee for the present claim amendments has been calculated to be \$0, if the Commissioner determines that a fee is due, please charge the required fee to Deposit Account 501784.

Dated: February 26, 2004

Respectfully submitted,

Anne M. Coughlin

Reg. No. 43,564

ECOPIA BIOSCIENCES INC.

7290 Frederick-Banting

Saint-Laurent (Quebec) H4S 2A1

Canada

Tel.: (514) 336-2700 fax: (514) 336-8827



Imafe

FW Box-Sequence  
1652  
4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Chris M. Farnet et al.

Serial No.: 09/976,059

Filed: Oct. 15, 2001

Examiner: Kathleen M. Kerr

Group Art Unit: 1652

Attorney docket no. 3002-2US  
(formerly 3019-US)

For: GENE CLUSTER FOR RAMOPLANIN BIOSYNTHESIS

RESPONSE TO RESTRICTION REQUIRMENT AND REQUEST FOR  
RECONSIDERATION UNDER 37 CFR §1.143

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed on September 26, 2003, please amend the application as follows.

Enclosed herewith is: (i) a Substitute Sequence Listing; (ii) a Petition to extend the time for response to the September 26, 2003 Office Action for 5 months from October 26, 2003 to and including March 26, 2003, with provision for the required fee; (iii) a Fee Transmittal Sheet which estimates the fee for the new claims 25-45 added herein; and (iv) a Supplemental Information Disclosure Statement accompanied by a form PTO-1449.

In the Claims:

Please cancel claims 1-24 without prejudice.

Please add new claims 25-45 as follows: